385 results on '"Asaoku, Hideki"'
Search Results
2. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma
3. Prognostic Significance of New-Onset Atrial Fibrillation in Patients With Non-Hodgkin's Lymphoma Treated With Anthracyclines
4. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
5. Supplementary Data from Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
6. Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study
7. Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
8. Association between IgG4-related disease and progressively transformed germinal centers of lymph nodes
9. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease
10. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results
11. Concurrent administration of darbepoetin alfa, cyclosporine A, and prednisolone is useful for T cell large granular lymphocyte leukemia associated with myelodysplastic syndrome complicated by Coombs-negative hemolytic anemia
12. Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)
13. A duodenal follicular lymphoma associated with the lesion mimicking MALT lymphoma in terminal ileum and Bauhin valve
14. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
15. CD56 expression in human myeloma cells derived from the neurogenic gene expression: possible role of the SRY-HMG box gene, SOX4
16. Survival of Multiple Myeloma Patients Aged 65–70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation
17. IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33(+) myeloma cells
18. Induction of Multilineage Markers in Human Myeloma Cells and Their Down-Regulation by Interleukin 6
19. An Increase in MPC-1- and MPC-1-CD45+ Immature Myeloma Cells in the Progressive States of Bone Marrow Plasmacytosis: The Revised Phenotypic Classification of Monoclonal Marrow Plasmacytosis (MOMP-2005)
20. Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group
21. Outcomes of methotrexate‐associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease‐modifying anti‐rheumatic drugs
22. Primary pulmonary collision tumor comprising squamous cell carcinoma and mucosa-associated lymphoid tissue lymphoma
23. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
24. Central nervous system involvement in intravascular large B-cell lymphoma: A retrospective analysis of 109 patients
25. Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
26. Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow
27. PREDICTIVE VALUE OF ENDOSCOPY AND ENDOSCOPIC ULTRASONOGRAPHY FOR REGRESSION OF GASTRIC DIFFUSE LARGE B-CELL LYMPHOMAS AFTER HELICOBACTER PYLORI ERADICATION
28. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma
29. Galectin-1 supports the survival of CD45RA(−) primary myeloma cells in vitro
30. Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not
31. Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma
32. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma
33. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications
34. A possible role for the loss of CD27–CD70 interaction in myelomagenesis
35. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma
36. MPC-1- CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas
37. Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma
38. A specific chromosome abnormality of t(4;12)(q11-12;p13) in CD7 sup + acute leukaemia
39. Emergence of Karyotypically unrelated clone in remission of de novo acute myeloblastic leukaemias
40. Restricted chromosome breakpoint sites on 11q22–q23.1 and 11q25 in various hematological malignancies without MLL/ALL-1 gene rearrangement
41. Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era
42. Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis
43. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma
44. Intravascular Large B-cell Lymphoma with a Pulmonary [18F]-Fluorodeoxyglucose Uptake
45. Watch-and-wait policyversusrituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma
46. Successful haploidentical stem cell transplantation with prophylactic administration of liposomal amphotericin B after invasive pulmonary zygomycosis
47. A Case of Sleep Apnea Syndrome in Amyloidosis Treated With Adaptive Servo-Ventilation
48. Multiple myeloma: From the clinical site
49. A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma
50. Watch‐and‐wait policy versus rituximab‐combined chemotherapy in Japanese patients with intestinal follicular lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.